Pediatric Clinics of North America - CIPERJ

ORAL IRON CHELATORS
479
[12] Borgna-Pignatti C, De Stefano P, Zonta L, et al. Growth and sexual maturation in
thalassemia major. J Pediatr 1985;106:150–5.
[13] Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major
in North America. Blood 2004;104(1):34–9.
[14] Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin
concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol
1993;42:81–5.
[15] Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily
oral iron chelator, in patients with beta-thalassemia. Blood 2006;107(9):3455–62.
[16] Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox
versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Br J Haematol 2007;136(3):501–8.
[17] Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with
homozygous beta-thalassemia. N Engl J Med 1994;331(9):574–8.
[18] Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term
monitoring of serum ferritin to predict complications of iron overload in thalassaemia major.
Br J Haematol 2000;110(4):971–7.
[19] Files B, Brambilla D, Kutlar A, et al. Longitudinal changes in ferritin during chronic transfusion:
a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr
Hematol Oncol 2002;24(4):284–90.
[20] Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in
transfusion independent thalassemia patients as compared to regularly transfused thalassemia
and sickle cell patients. Pediatr Blood Cancer 2007;49(3):329–32.
[21] Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body
iron stores in thalassemia major. N Engl J Med 2000;343(5):327–31.
[22] Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia.
Blood 1997;89(3):739–61.
[23] Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341(2):99–109.
[24] Villeneuve JP, Bilodeau M, Lepage R, et al. Variability in hepatic iron concentration
measurement from needle-biopsy specimens. J Hepatol 1996;25(2):172–7.
[25] Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for
the early diagnosis of myocardial iron overload. Eur Heart J 2001;22(23):2171–9.
[26] Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of
siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2*
cardiovascular magnetic resonance. Br J Haematol 2004;127(3):348–55.
[27] Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of
human iron stores. N Engl J Med 1982;307(27):1671–5.
[28] Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily
oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006;
91(10):1343–51.
[29] Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade,
ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine
in thalassemia patients with transfusional iron overload. Haematologica 2006;91(7):873–80.
[30] Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone
in patients with thalassemia major. N Engl J Med 1995;332(14):918–22.
[31] Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK
workshop. Blood 2003;101(1):15–9.
[32] St. Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and
imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;
105(2):855–61.
[33] Westwood MA, Wonke B, Maceira AM, et al. Left ventricular diastolic function compared
with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload
in thalassemia major. J Magn Reson Imaging 2005;22(2):229–33.